[Clinical consequences of intranasal insulin therapy in insulin-dependent diabetes mellitus].
Metabolic control, hypoglycaemia frequency and nasal mucosal physiology were evaluated in 31 insulin-dependent diabetics treated with intranasal insulin at mealtimes for one month and with subcutaneous fast-acting insulin for another month in a randomized crossover trial. During both periods the patients were treated with intermediate-acting insulin at bedtime. Six of the patients were withdrawn from the study during intranasal insulin therapy due to metabolic dysregulation. Insulin concentrations increased more rapidly and decreased more quickly during intranasal as compared with subcutaneous insulin administration. Metabolic control, assessed by haemoglobin A1c concentrations, deteriorated after intranasal as compared with subcutaneous insulin therapy. The bioavailability of intranasally applied insulin was low, since intranasal insulin doses were approximately 20 times higher than subcutaneous doses. The frequency of hypoglycemia was similar during intranasal and subcutaneous insulin therapy, and nasal mucosal physiology was unaffected after intranasal insulin. We conclude that due to low bioavailability and to a high rate of therapeutic failure, intranasal insulin treatment is not a realistic alternative to subcutaneous insulin injections at the present time.
Hilsted
J C
JC
Medicinsk endokrinologisk afdeling, Hvidovre Hospital.
Madsbad
S
S
Rasmussen
M H
MH
Hvidberg
A
A
Krarup
T
T
Ipsen
H
H
Hansen
B
B
Pedersen
M
M
Djurup
R
R
Oxenbøll
B
B
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D001682:Biological Availability; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007003:Hypoglycemia; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged
D007004:Hypoglycemic Agents; D007328:Insulin
Kliniske konsekvenser af intranasal insulinbehandling ved insulinkraevende diabetes mellitus.